BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261023
DTSTAMP:20260630T110639Z
CREATED:20260630T110639Z
LAST-MODIFIED:20260630T110639Z
UID:43858-1792454400-1792713599@www.pharmajournalist.com
SUMMARY:4th Covalent Drug Discovery & Development Summit
DESCRIPTION:4th Covalent Drug Discovery & Development Summit (October 20–22\, Boston\, MA) \nCovalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns\, advances in chemistry\, screening technologies\, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. \nAs the field evolves\, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection\, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes. \nThe 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists\, chemical biologists\, translational scientists\, and early clinical leaders\, the meeting delivers a truly end-to-end perspective across covalent drug development\, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs. \nAcross two conference days and interactive workshops\, attendees will gain practical\, actionable insights to: \n\nDesign safer\, more selective covalent compounds using novel warheads and structure-guided approaches\nDe-risk development through advanced toxicity\, reactivity\, and safety assessment strategies\nIntegrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions\nExpand the druggable space by targeting new residues and previously undruggable biology\n\nWith case studies spanning AI-driven discovery\, chemoproteomics\, kinetic assays\, and translational workflows\, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies. \nBringing together 80+ senior leaders from pharma\, biotech\, and academia\, this is a highly curated environment for deep technical exchange\, collaboration\, and real-world problem solving. \nWhether you are optimizing discovery\, scaling translational strategy\, or preparing for the clinic\, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.
URL:http://www.pharmajournalist.com/event/4th-covalent-drug-discovery-development-summit/
LOCATION:Hampton Inn Boston Seaport District\, 670 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR